doi:10.3390/biology5040053
The glucagon-like peptide-1 receptor agonist semaglutide is approved for the treatment of type 2 diabetes and obesity and has an established safety profile
All PK samples were assumed to be at steady state (with the exception of the observation at week 2 in SUSTAIN 6), and previous doses were assumed to be according to the study plan
The following step-by-step approach represents best practices synthesized from provider experience and patient outcomes
Patients receiving Foundayo 17.2 mg lost an average of 19.7 pounds, compared with 11.0 pounds among those receiving oral semaglutide 14 mg, corresponding to a 73.6% greater relative weight reduction. Notably, 37.1% of patients receiving the higher dose of Foundayo achieved an A1C below 5.7%, a threshold generally considered within the normal glycemic range, compared with 12.5% of patients receiving oral semaglutide. "ACHIEVE-3 provides the first head-to-head data on oral GLP-1s in type 2 diabetes, with orforglipron showing greater A1C and weight reductions than oral semaglutide," said Julio Rosenstock, MD, clinical professor of medicine at the University of Texas Southwestern Medical Center and lead investigator for ACHIEVE-3. What did the additional ACHIEVE studies show